stem-cell-congress-cardiology-2018-posters

Biomedical Research

Volume 29

Page 50

allied

academies

CARDIOLOGY AND CARDIOVASCULAR MEDICINE

STEM CELLS AND REGENERATIVE MEDICINE

International Conference on

J u n e 1 8 - 1 9 , 2 0 1 8 | O s a k a , J a p a n

Joint Event on

THE ROLE OF DOBUTAMINE DOSE ON THE CARDIAC

PARAMETERS

Rabindra Nath Das

The University of Burdwan, India

Objectives:

The report presents the effects of dobutamine dose on the cardiac parameters such as blood pressures (basal,

systolic, diastolic & maximum), heart rates (basal, peak & maximum), baseline cardiac ejection fraction, and ejection fraction on

dobutamine dose.

Background:

There is a little literature about the effects of dobutamine dose on the cardiac parameters.

Materials and Methods:

The effects of dobutamine dose on the cardiac parameters have been examined based on a real

echocardiography stress data set, collected at University of California, Los Angeles on 558 patients with 31 explanatory variables/

factors. The distribution of the considered cardiac parameters is gamma with non-constant variance. So, they have been analyzed

by joint generalized linear gamma models.

Results:

The mean basal blood pressure (BBP) decreases as the double product of maximum heart rate (MHR) & maximum blood

pressure (MBP) at dobutamine dose (DPMAXDO) (P<0.001) increases, while the variance of BBP increases as the DPMAXDO

(P<0.001) increases. The mean systolic blood pressure (SBP) increases as the dobutamine dose (DOSE) (P=0.032) increases,

while the mean SBP increases as the DPMAXDO (P<0.001) decreases. Mean MBP increases with the increase in DPMAXDO

(P<0.001). The mean baseline cardiac ejection fraction (BEF) decreases as the DOSE (P=0.025) increases. The mean ejection

fraction on dobutamine dose (DOBEF) increases as the DOSE (P=0.011) increases, while the variance of DOBEF increases as the

dobutamine dose at maximum double product (DOBDOSE) (P=0.001) decreases. The mean basal heart rate (BHR) increases as

the DPMAXDO (P<0.001), or DOBDOSE (P=0.074) decreases. The mean peak heart rate (PHR), or maximum heart rate (MHR)

increases as the DPMAXDO (P<0.001) increases, while the variance of PHR, (MHR) increases as the DOBDOSE (P<0.001)

decreases (increases). On the other hand, dobutamine dose is associated with many cardiac parameters such as SBP, MBP, new

myocardial infraction (new MI), history of MI (hxofMI) etc.

Conclusions:

Only the dobutamine dose effects are observed on SBP, MBP, DOBEF, newMI, histMI, etc, while the joint effects of

dobutamine (DPMAXDO and DOBDOSE) are observed on each cardiac parameter. The results are new inputs in the dobutamine

dose study literature.

Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C2-006